(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Public Parks in the USA - 2Deadly heat worldwide prompts $300 million for climate health research at COP30
- 3With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge
- 4Kids may be more likely to get the new ‘Cicada’ variant of Covid-19, scientists say. Here’s what to know about BA.3.2
- 5Wedding trip Objections in the US
- 6 Famous Cell phone Brands All over The Planet
- The Way to Fruitful Weight reduction: Individual Wellbeing Excursions
- More than half way to the moon, the Artemis II astronauts are grappling with a toilet problem
- New movies to watch this weekend: See 'We Bury the Dead' in theaters, rent 'Wicked: For Good,' stream 'The Unbreakable Boy' on Starz
- Shrewd Home Gadgets to Save Energy
- Lawsuit claims ChatGPT exacerbated man's delusions leading to murder-suicide
- 'Harmonious' meeting between Merz, Lula despite Belém controversy
- Germany records first wolf bite on human since repopulation
- How to see the Ursids, the final meteor shower of 2025
